statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J...

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC  Get Free Report) saw a large drop in short interest in March. As of March 15th, there was short interest totalling 26,600 shares, a drop of 35.9...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Sees Large Decline in Short Interest

StockNews.com upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC  Free Report) from a sell rating to a hold rating in a report issued on Tuesday morning.
A number of other brokerages...

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded to "Hold" at StockNews.com

StockNews.com cut shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC  Free Report) from a hold rating to a sell rating in a research report report published on Monday morning. Other analysts have...

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Downgraded by StockNews.com

On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation Oral Plogosertib Preclinical Data Support Precision...

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

StockNews.com upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC  Free Report) from a sell rating to a hold rating in a research note released on Thursday morning. Several other...

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Raised to "Hold" at StockNews.com

Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphomaBERKELEY HEIGHTS, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel...

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cyclacel Pharmaceuticals receives $2.9M R&D tax credit

BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Volume	180,812.00
52-Wk High	$13.20
52-Wk Low	$1.41

CYCC Cyclacel Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals